FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1275343739> ?p ?o ?g. }

• W1275343739 endingPage "e1001119" @default.
• W1275343739 startingPage "e1001119" @default.
• W1275343739 abstract "Background Artemisinin-based combination therapies (ACTs) are the mainstay for the management of uncomplicated malaria cases. However, up-to-date data able to assist sub-Saharan African countries formulating appropriate antimalarial drug policies are scarce. Methods and Findings Between 9 July 2007 and 19 June 2009, a randomized, non-inferiority (10% difference threshold in efficacy at day 28) clinical trial was carried out at 12 sites in seven sub-Saharan African countries. Each site compared three of four ACTs, namely amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL), or chlorproguanil-dapsone-artesunate (CD+A). Overall, 4,116 children 6–59 mo old with uncomplicated Plasmodium falciparum malaria were treated (1,226 with AL, 1,002 with ASAQ, 413 with CD+A, and 1,475 with DHAPQ), actively followed up until day 28, and then passively followed up for the next 6 mo. At day 28, for the PCR-adjusted efficacy, non-inferiority was established for three pair-wise comparisons: DHAPQ (97.3%) versus AL (95.5%) (odds ratio [OR]: 0.59, 95% CI: 0.37–0.94); DHAPQ (97.6%) versus ASAQ (96.8%) (OR: 0.74, 95% CI: 0.41–1.34), and ASAQ (97.1%) versus AL (94.4%) (OR: 0.50, 95% CI: 0.28–0.92). For the PCR-unadjusted efficacy, AL was significantly less efficacious than DHAPQ (72.7% versus 89.5%) (OR: 0.27, 95% CI: 0.21–0.34) and ASAQ (66.2% versus 80.4%) (OR: 0.40, 95% CI: 0.30–0.53), while DHAPQ (92.2%) had higher efficacy than ASAQ (80.8%) but non-inferiority could not be excluded (OR: 0.35, 95% CI: 0.26–0.48). CD+A was significantly less efficacious than the other three treatments. Day 63 results were similar to those observed at day 28. Conclusions This large head-to-head comparison of most currently available ACTs in sub-Saharan Africa showed that AL, ASAQ, and DHAPQ had excellent efficacy, up to day 63 post-treatment. The risk of recurrent infections was significantly lower for DHAPQ, followed by ASAQ and then AL, supporting the recent recommendation of considering DHAPQ as a valid option for the treatment of uncomplicated P. falciparum malaria. Trial Registration ClinicalTrials.gov NCT00393679; Pan African Clinical Trials Registry PACTR2009010000911750 Please see later in the article for the Editors' Summary" @default.
• W1275343739 created "2016-06-24" @default.
• W1275343739 date "2011-11-08" @default.
• W1275343739 modified "2023-09-26" @default.
• W1275343739 title "A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial" @default.
• W1275343739 cites W1838568970 @default.
• W1275343739 cites W1856406213 @default.
• W1275343739 cites W1961560774 @default.
• W1275343739 cites W1970272857 @default.
• W1275343739 cites W1971837596 @default.
• W1275343739 cites W1974243165 @default.
• W1275343739 cites W1991442399 @default.
• W1275343739 cites W2015380911 @default.
• W1275343739 cites W2018285406 @default.
• W1275343739 cites W2021293206 @default.
• W1275343739 cites W2022535206 @default.
• W1275343739 cites W2023282331 @default.
• W1275343739 cites W2026129338 @default.
• W1275343739 cites W2036368368 @default.
• W1275343739 cites W2038910210 @default.
• W1275343739 cites W2057048575 @default.
• W1275343739 cites W2096913021 @default.
• W1275343739 cites W2100350165 @default.
• W1275343739 cites W2105812381 @default.
• W1275343739 cites W2109191053 @default.
• W1275343739 cites W2111539591 @default.
• W1275343739 cites W2111813303 @default.
• W1275343739 cites W2114583322 @default.
• W1275343739 cites W2119626572 @default.
• W1275343739 cites W2122967261 @default.
• W1275343739 cites W2123129595 @default.
• W1275343739 cites W2124436523 @default.
• W1275343739 cites W2128743785 @default.
• W1275343739 cites W2132966541 @default.
• W1275343739 cites W2136839832 @default.
• W1275343739 cites W2139477348 @default.
• W1275343739 cites W2139891194 @default.
• W1275343739 cites W2143229710 @default.
• W1275343739 cites W2145891164 @default.
• W1275343739 cites W2149251475 @default.
• W1275343739 cites W2154810899 @default.
• W1275343739 cites W2155517825 @default.
• W1275343739 cites W2157912408 @default.
• W1275343739 cites W2163644520 @default.
• W1275343739 cites W2163995382 @default.
• W1275343739 cites W2166357496 @default.
• W1275343739 cites W2166681862 @default.
• W1275343739 cites W2170005697 @default.
• W1275343739 cites W2188296303 @default.
• W1275343739 cites W4297845758 @default.
• W1275343739 doi "https://doi.org/10.1371/journal.pmed.1001119" @default.
• W1275343739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22087077" @default.
• W1275343739 hasPublicationYear "2011" @default.
• W1275343739 type Work @default.
• W1275343739 sameAs 1275343739 @default.
• W1275343739 citedByCount "119" @default.
• W1275343739 countsByYear W12753437392012 @default.
• W1275343739 countsByYear W12753437392013 @default.
• W1275343739 countsByYear W12753437392014 @default.
• W1275343739 countsByYear W12753437392015 @default.
• W1275343739 countsByYear W12753437392016 @default.
• W1275343739 countsByYear W12753437392017 @default.
• W1275343739 countsByYear W12753437392018 @default.
• W1275343739 countsByYear W12753437392019 @default.
• W1275343739 countsByYear W12753437392020 @default.
• W1275343739 countsByYear W12753437392021 @default.
• W1275343739 countsByYear W12753437392022 @default.
• W1275343739 crossrefType "journal-article" @default.
• W1275343739 hasBestOaLocation W12753437391 @default.
• W1275343739 hasConcept C126322002 @default.
• W1275343739 hasConcept C156957248 @default.
• W1275343739 hasConcept C168563851 @default.
• W1275343739 hasConcept C203014093 @default.
• W1275343739 hasConcept C2776120307 @default.
• W1275343739 hasConcept C2776623344 @default.
• W1275343739 hasConcept C2776992834 @default.
• W1275343739 hasConcept C2778048844 @default.
• W1275343739 hasConcept C2778059366 @default.
• W1275343739 hasConcept C2778371730 @default.
• W1275343739 hasConcept C2778629330 @default.
• W1275343739 hasConcept C2780780316 @default.
• W1275343739 hasConcept C2781160685 @default.
• W1275343739 hasConcept C71924100 @default.
• W1275343739 hasConceptScore W1275343739C126322002 @default.
• W1275343739 hasConceptScore W1275343739C156957248 @default.
• W1275343739 hasConceptScore W1275343739C168563851 @default.
• W1275343739 hasConceptScore W1275343739C203014093 @default.
• W1275343739 hasConceptScore W1275343739C2776120307 @default.
• W1275343739 hasConceptScore W1275343739C2776623344 @default.
• W1275343739 hasConceptScore W1275343739C2776992834 @default.
• W1275343739 hasConceptScore W1275343739C2778048844 @default.
• W1275343739 hasConceptScore W1275343739C2778059366 @default.
• W1275343739 hasConceptScore W1275343739C2778371730 @default.
• W1275343739 hasConceptScore W1275343739C2778629330 @default.
• W1275343739 hasConceptScore W1275343739C2780780316 @default.
• W1275343739 hasConceptScore W1275343739C2781160685 @default.
• W1275343739 hasConceptScore W1275343739C71924100 @default.
• W1275343739 hasIssue "11" @default.

• next